10
CIPRÉS-FLORES ET AL.
exposure in the male rat hippocampus. Neurochemistry Research, 39,
1776–1786.
Lee, S., & Barron, M. G. (2015). Development of 3D-QSAR model for ace-
tylcholinesterase inhibitors using a combination of fingerprint, molecu-
lar docking, and structure-based pharmacophore approaches.
Toxicological Sciences, 148, 60–70.
Lewczuk, P., Mroczko, B., Fagan, A., & Kornhuber, J. (2014). Biomarkers of
Alzheimer's disease and mild cognitive impairment: A current perspec-
tive. Advances in Medical Sciences, 60, 76–82.
Farfán-García, E. D., Pérez-Rodríguez, M., Espinosa-García, C., Castillo-
Mendieta, N. T., Maldonado-Castro, M., Querejeta, E., … Soriano-
Ursúa, M. A. (2016). Disruption of motor behavior and injury to the
CNS induced by 3-thienylboronic acid in mice. Toxicology and Applied
Pharmacology, 307, 130–137.
Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G.E., Robb, M.A.
Cheeseman, J.R., …Fox, D.J. (2009). Gaussian, Inc., Gaussian 09, Revi-
sion E. 01, Pittsburgh PA.
Lippa, C. F. (2015). Alzheimer's disease: A financial crisis and the common-
wealth of Pennsylvania. American Journal of Alzheimer's Disease &
Other Dementias, 30(2), 117–118.
Gallucci, M., Spagnolo, P., Aricò, M., & Grossi, E. (2016). Predictors of
response to cholinesterase inhibitors treatment of Alzheimer's disease:
Date mining from the TREDEM registry. Journal of Alzheimer's Disease,
50, 969–979.
Gao, X. H., Tang, J. J., Liu, H. R., Liu, L. B., & Liu, Y. Z. (2019). Structure-
activity study of fluorine or chlorine-substituted cinnamic acid deriva-
tives with tertiary amine side chain in acetylcholinesterase and but-
yrylcholinesterase inhibition. Drug Development Research, 80, 438–445.
Garrido-Acosta, O., Meza-Toledo, S. E., Anguiano-Robledo, L., Valencia-
Hernández, I., & Chamorro-Cevallos, G. (2014). Adaptation of Lorke´s
method to determine and compare ED50 values: The cases ot two
anticonvulsant drugs. Journal of Pharmacology and Toxicology Methods,
70, 66–69.
Liu, X., Ma, L., Li, H. H., Huang, B., Li, Y. X., Tao, Y. Z., & Ma, L. (2015).
β-Arrestin-biased signaling mediates memory reconsolidation. Proceed-
ings of Natural Academy of Sciences, USA, 112, 4483–4488.
Liu, X., Ye, K., & Weinshenker, D. (2015). Norepinephrine protects against
amyloid-β toxicity via TrkB. Journal of Alzheimer's Disease., 44, 251–260.
Lonergan, M. H., Olivera-Figueroa, L. A., Pitman, R. K., & Brunet, A. (2013).
Propranolol's effects on the consolidation and reconsolidation of long-
term emotional memory in healthy participants: A meta-analysis. Jour-
nal of Psychiatry & Neurosciences., 38, 222–231.
Lương, K. Y., & Nguyen, L. T. (2013). The role of Beta-adrenergic receptor
blockers in Alzheimer's disease: Potential genetic and cellular signaling
mechanisms. American Journal of Alzheimer's Disease & Other Demen-
tias, 28, 427–439.
Greig, N. H., Reale, M., & Tata, A. M. (2013). New pharmacological
approaches to the cholinergic system: An overview on muscarinic
receptor ligands and cholinesterase inhibitors. Recent Patents on CNS
Drug Discovery, 8, 123–141.
Macdonald, I. R., Rockwood, K., Martin, E., & Darvesh, S. (2014). Cholines-
terase inhibition in Alzheimer's disease: Is specificity the answer? Jour-
nal of Alzheimer's Disease, 42, 379–384.
Mielke, M. M., Vemuri, P., & Rocca, W. A. (2014). Clinical epidemiology of
Alzheimer's disease: Assessing sex and gender differences. Clinical Epi-
demiology, 6, 37.
Hallerbäck, B., Ander, S., & Glise, H. (1987). Effect of combined blockade
of beta-adrenoceptors and acetylcholinesterase in the treatment of
postoperative ileus after cholecystectomy. Scandinavian Journal of Gas-
troenterology, 22, 420–424.
Hernández-Rodríguez, M., Correa-Basurto, J., Martínez-Ramos, F., Padilla-
Martínez, I. I., Benítez-Cardoza, C. G., Mera-Jiménez, E., & Rosales-
Hernández, M. C. (2014). Design of multi-target compounds as AChE,
BACE1, and amyloid-β(1-42) oligomerization inhibitors: In silico and
in vitro studies. Journal of Alzheimer's Disease, 41, 1073–1085.
Herrmann, N., Chau, S. A., Kircanski, I., & Lanctôt, K. L. (2011). Current and
emerging drug treatment options for Alzheimer's disease: A systematic
review. Drugs, 71, 2031–2065.
Mitsushima, D., Takase, K., Funabashi, T., & Kimura, F. (2008). Gonadal ste-
roid hormones maintain the stress-induced acetylcholine release in the
hippocampus: Simultaneous measurements of the extracellular acetyl-
choline and serum corticosterone levels in the same subjects. Endocri-
nology, 149, 802–811.
Mohammadi-Khanaposhtani, M., Saeedi, M., Zafarghandi, N. S.,
Mahdavi, M., Sabourian, R., Razkenari, E. K., … Akbarzadeh, T. (2015).
Potent acetylcholinesterase inhibitors: Design, synthesis, biological
evaluation, and docking study of acridone linked to 1,2,3-triazole
derivatives. European Journal of Medicinal Chemistry, 92, 799–806.
Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E.,
Belew, R. K., & Olson, A. J. (1998). Automated docking using a
Lamarckian genetic algorithm and an empirical binding free energy
function. Journal of Computational Chemistry, 19, 1639–1662.
Nygaard, H. B. (2013). Current and emerging therapies for Alzheimer's dis-
ease. Clinical Therapeutics, 35, 1480–1489.
Hogan, D. B. (2014). Long-term efficacy and toxicity of cholinesterase
inhibitors in the treatment of Alzheimer disease. Canadian Journal of
Psychiatry, 59, 618–623.
Hugo, J., & Ganguli, M. (2014). Dementia and cognitive impairment: Epide-
miology, diagnosis, and treatment. Clinics in Geriatric Medicine, 30,
421–442.
Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD: Visual molecular
dynamics. Journal of Molecular Graphics, 14, 33–38.
Saber, A. J., & Cain, D. P. (2003). Combined beta-adrenergic and cholinergic
antagonism produces behavioral and cognitive impairments in the water
maze: Implications for Alzheimer disease and pharmacotherapy with
beta-adrenergic antagonists. Neuropsychopharmacology, 28, 1247–1256.
Sahin, Z., Ertas, M., Bender, C., Bülbül, E. F., Berk, B., Biltekin, S. N., …
Demirayak, S¸. (2018). Thiazole-substituted benzoylpiperazine deriva-
tives as acetylcholinesterase inhibitors. Drug Development Research,
79, 406–425.
Ihl, R., Bunevicius, R., Frölich, L., Winblad, B., Schneider, L. S., Dubois, B., …
WFSBP Task Force on Mental Disorders in Primary Care. (2015).
World Federation of Societies of Biological Psychiatry guidelines for
the pharmacological treatment of dementias in primary care. Interna-
tional Journal of Psychiatry in Clinical Practice, 19(1), 2–7.
Khan, I., Ibrar, A., Zaib, S., Ahmad, S., Furtmann, N., Hameed, S., … Iqbal, J.
(2014). Active compounds from a diverse library of triazolothiadiazole
and triazolothiadiazine scaffolds: Synthesis, crystal structure determi-
nation, cytotoxicity, cholinesterase inhibitory activity, and binding
mode analysis. Bioorganic & Medicinal Chemistry, 22, 6163–6173.
Kumar, A., & Singh, A. (2015). A review on Alzheimer's disease pathophysi-
ology and its management: An update. Pharmacological Reports, 67(2),
195–203.
Santacruz Biotechnology Inc. (2014a). Safety data sheet donepezil-13C3
hydrochloride.
Retrieved
from
Santacruz Biotechnology Inc. (2014b) Safety data sheet galanthamine
hydrobromide.
Retrieved
from
Schramm, M. J., Everitt, B. J., & Milton, A. L. (2015). Bidirectional modulation
of alcohol-associated memory reconsolidation through manipulation of
adrenergic Signaling. Neuropsychopharmacology, 41, 1103–1111.
Singh, A. K., & Spassova, D. (1998). Effects of hexamethonium, phenothia-
zines, propranolol and ephedrine on acetylcholinesterase
Lambert, M. A., Bickel, H., Prince, M., Fratiglioni, L., Von Strauss, E.,
Frydecka, D., … Reynish, E. L. (2014). Estimating the burden of early
onset dementia; systematic review of disease prevalence. European
Journal of Neurology, 21(4), 563–569.